Article Text
Abstract
Introduction/Background Strategy of treatment in patients with recurrent ovarian cancer (OC) dependents on platinum-free interval (PFI). We aimed to compare survival in ‘platinum resistant’ OC patients who received platinum-based or non-platinum chemotherapy at first relapse in real world practice based.
Methodology Data of OC patients treated with primary debulking surgery and standard chemotherapy (paclitaxel/platinum analogs) between January 1, 2011 and December 31, 2011 were extracted from Polish National Health Fund Database. Further overall survival (OS) was compared between patients who received any type of chemotherapy up to 6 months PFI.
Results 17% (227/1369) patients classified as ‘platinum-resistant’ by the 6-month threshold of PFI and 29% (66/227) of those group, were treated with Pt-based chemotherapy at second line. Median OS after platinum-based 2-nd line chemotherapy was significantly longer compared to non- platinum chemotherapy group (median OS was 28.1 months, 95% CI: 23.3–42.0 vs. 16.4 months, 95% CI: 13.1–21.0; HR=0.71, 95% CI, 0.51–0.99; P=0.049). This effect was seen, among patients with PFI of 3–6 months (median OS was, 28.1 months, 95% CI: 23.1–42.0 vs 14.3 months, 95% CI: 10.4–40.5, respectively; HR=0.61, 95%CI, 0.39–0.96; P=0.0336). but not in PFI <3months group (HR=0.88, 95% CI, 0.52 to 1.49, P=0.6342).
Conclusion Our results from real world data based on nationwide population cohort study shows that six-months PFI as an arbitrary threshold for subsequent Pt-based chemotherapy is questionable. Biomarkers of platinum sensitivity are needed to identify potential responders, especially in group of patients with PFI 3–6 months.
Disclosure Nothing to disclose.